Filter your search results
Problem addressed
Title | Author(s) | Category | Type | Year |
---|---|---|---|---|
Rediscovering MDMA (ecstasy): the role of the American chemist Alexander T. Shulgin | Benzenhoefer U, Passie T | Journal Article | 2010 | |
Polydrug use among 15- to 16-year olds: Similarities and differences in Europe | Olszewskia D, Matiasa J, Monshouwerbc K & Kokkevi A | Journal Article | 2009 | |
The risk of psychotic symptoms associated with recreational methamphetamine use | McKetin R, Hickey K, Devlin K et al. | Journal Article | 2010 | |
Cardiovascular disease risk factors and symptoms among regular psychostimulant users | Darke S, Torok M, Kaye S et al. | Journal Article | 2010 | |
Nightlife young risk behaviours in Mediterranean versus other European cities: are stereotypes true? | Calafat A, Blay NT, Hughes K et al. | Journal Article | 2010 | |
The confusing case of NRG-1 | Brandt SG, Sumnall HR, Measham F et al. | Journal Article | 2010 | |
Metabolism of designer drugs of abuse: an updated review | Meyer MR, Maurer HH | Journal Article | 2010 | |
Mephedrone, new kid for the chop? | Winstock AR, Mitcheson LR, Deluca P et al. | Journal Article | 2011 | |
Instability of the ecstasy market and a new kid on the block: mephedrone | Brunt TM, Poortman A, Niesink RJ et al. | Journal Article | 2010 | |
The impact of gamma hydroxybutyrate (GHB) legal restrictions on patterns of use: Results from an International Survey | Anderson IB, Kim-Katz S, Dyer JE et al. | Journal Article | 2010 |